Global Orphan Drug Market To Surpass USD 100 Billion by 2015

It is also expected that the growth in the orphan drugs segment would be more than the growth in the non-orphan drugs segment.

Release Date: 30-Apr-2014



The global pharmaceutical industry has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon. Thus, due to significant competition from generics and the current economic situation, the focus area of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to investing in the new business model, which is also called orphan drugs. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.

 

The major drivers for companies to increasingly invest in orphan drugs include government incentives for drug development and strong support from the FDA and EU Commission in special protocols. Inspite of pharma companies facing many obstacles in this field, this segment of orphan drugs is likely to have the potential to provide the key to recovery and stability within the market.

 

 

Global Orphan Drug Market Report Findings:

 

 

For More Information Visit: “Global Orphan Drug Market Outlook 2018”

Need custom market research solution? We can help you with that too.